{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:02:57Z","timestamp":1791846177902,"version":"4.3.4"},"reference-count":409,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>According to the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC), type 2 diabetes mellitus (T2DM) remains a major public health issue with a considerable impact on human life, affecting over 38 million Americans of all ages, and an estimated 529 million people worldwide. It is a significant risk factor for polyneuropathy, eye problems, coronary artery disease (CAD), renal disease, heart disease, stroke, and peripheral artery disease (PAD). Nearly 9 million Americans with diabetes are unaware of their condition and, therefore, do not receive health care to prevent disease progression and complications. With T2DM being a condition that leads to increased demand for health care services due to its long-term, persistent nature and its incremental impact on the body, early diagnosis and timely initiation of effective treatments are essential. Despite the effect of metabolic memory in the development of diabetes-related complications, early intervention helps decelerate disease progression, reduce complications, and ultimately improve survival. Various blood-based biomarkers have been identified, which hold great promise to streamline the mechanisms underlying T2DM and its progression from insulin resistance and prediabetes to diabetes and end-stage diabetes. However, the greatest need is to identify and utilize reliable biomarkers that can help to assess pharmacological treatment response and guide efforts to improve insulin sensitivity, preserve pancreatic beta-cell function, and prevent or delay complications. This review explores the clinical utility of promising biomarkers and assess their potential to support more personalized pharmacological approaches tailored to the individual characteristics of T2DM patients.<\/jats:p>","DOI":"10.3390\/molecules30224448","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T16:49:51Z","timestamp":1763484591000},"page":"4448","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Potential Molecular Biomarkers for Predicting and Monitoring Complications in Type 2 Diabetes Mellitus"],"prefix":"10.3390","volume":"30","author":[{"given":"Zia","family":"Shariat-Madar","sequence":"first","affiliation":[{"name":"Division of Pharmacology, School of Pharmacy, University of Mississippi, Oxford, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-2992","authenticated-orcid":false,"given":"Fakhri","family":"Mahdi","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, School of Pharmacy, University of Mississippi, Oxford, MS 38677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"ref_1","unstructured":"The International Diabetes Federation (IDF) (2025, July 30). Diabetes Facts and Figures. Available online: https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1420-P","DOI":"10.2337\/db24-1420-P","article-title":"1420-P: Global Burden and Trend of Type 2 DM in 38 OECD Countries from 1990\u20132019\u2014A Benchmarking Systematic Analysis","volume":"73","author":"Markandu","year":"2024","journal-title":"Diabetes"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.2040-1124.2011.00112.x","article-title":"Therapeutic management of diabetic kidney disease","volume":"2","author":"Koya","year":"2011","journal-title":"J. Diabetes Investig."},{"key":"ref_4","first-page":"575","article-title":"Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms","volume":"34","author":"Petrie","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4239\/wjd.v12.i4.383","article-title":"Diabetic heart disease: A clinical update","volume":"12","author":"Rajbhandari","year":"2021","journal-title":"World J. Diabetes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40139-020-00205-x","article-title":"Diabetic vasculopathy: Macro and microvascular injury","volume":"8","author":"Mota","year":"2020","journal-title":"Curr. Pathobiol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Galiero, R., Caturano, A., Vetrano, E., Beccia, D., Brin, C., Alfano, M., Di Salvo, J., Epifani, R., Piacevole, A., and Tagliaferri, G. (2023). Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043554"},{"key":"ref_8","unstructured":"World Health Organization (WHO) (2025, June 10). Diabete. Available online: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jdi.12105","article-title":"Effect of diabetes on stroke symptoms and mortality: Lessons from a recent large population-based cohort study","volume":"5","author":"Umemura","year":"2014","journal-title":"J. Diabetes Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e35285","DOI":"10.1097\/MD.0000000000035285","article-title":"Vascular complications of diabetes: A narrative review","volume":"102","author":"Lu","year":"2023","journal-title":"Medicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"C141","DOI":"10.1152\/ajpcell.00533.2022","article-title":"The hypothalamus as a key regulator of glucose homeostasis: Emerging roles of the brain renin-angiotensin system","volume":"325","author":"Pan","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.15585\/mmwr.mm6712a3","article-title":"Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality-United States, 2000\u20132014","volume":"67","author":"Benoit","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic Crises in Adult Patients With Diabetes","volume":"32","author":"Kitabchi","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/dme.12757","article-title":"Management of hyperosmolar hyperglycaemic state in adults with diabetes","volume":"32","author":"Scott","year":"2015","journal-title":"Diabet. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00125-024-06183-8","article-title":"Hyperglycaemic crises in adults with diabetes: A consensus report","volume":"67","author":"Umpierrez","year":"2024","journal-title":"Diabetologia"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wei, W.T., Lin, S.M., Hsu, J.Y., Wu, Y.Y., Loh, C.H., Huang, H.K., and Liu, P.P. (2022). Association between Hyperosmolar Hyperglycemic State and Venous Thromboembolism in Diabetes Patients: A Nationwide Analysis in Taiwan. J. Pers. Med., 12.","DOI":"10.3390\/jpm12020302"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Arabshomali, A., Bazzazzadehgan, S., Mahdi, F., and Shariat-Madar, Z. (2023). Potential Benefits of Antioxidant Phytochemicals in Type 2 Diabetes. Molecules, 28.","DOI":"10.3390\/molecules28207209"},{"key":"ref_18","first-page":"l1114","article-title":"Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: Review of acute decompensated diabetes in adult patients","volume":"365","author":"Donihi","year":"2019","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.2337\/dc06-9916","article-title":"Hyperglycemic Crises in Adult Patients With Diabetes: A consensus statement from the American Diabetes Association","volume":"29","author":"Kitabchi","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.2196\/jmir.2624","article-title":"Retrieving clinical evidence: A comparison of PubMed and Google Scholar for quick clinical searches","volume":"15","author":"Shariff","year":"2013","journal-title":"J. Med. Internet Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.annemergmed.2019.07.003","article-title":"Google Versus PubMed: Comparison of Google and PubMed\u2019s Search Tools for Answering Clinical Questions in the Emergency Department","volume":"75","author":"Morshed","year":"2020","journal-title":"Ann. Emerg. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.molmet.2019.06.016","article-title":"Biomarkers for type 2 diabetes","volume":"27","author":"Laakso","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/ATVBAHA.108.169722","article-title":"Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance","volume":"28","author":"Kim","year":"2008","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41586-024-07019-6","article-title":"Genetic drivers of heterogeneity in type 2 diabetes pathophysiology","volume":"627","author":"Suzuki","year":"2024","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Bazzazzadehgan, S., Shariat-Madar, Z., and Mahdi, F. (2025). Distinct Roles of Common Genetic Variants and Their Contributions to Diabetes: MODY and Uncontrolled T2DM. Biomolecules, 15.","DOI":"10.3390\/biom15030414"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2337\/db18-0537","article-title":"Epigenetics and Epigenomics: Implications for Diabetes and Obesity","volume":"67","author":"Rosen","year":"2018","journal-title":"Diabetes"},{"key":"ref_28","unstructured":"Masuo, K. (2013). Epigenetics of Glucose Metabolism and the Basis for T2DM Interventions. Type 2 Diabetes, IntechOpen."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/febs.16306","article-title":"Pathophysiology of type 2 diabetes and the impact of altered metabolic interorgan crosstalk","volume":"290","author":"Sanches","year":"2023","journal-title":"Febs. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/ITT.S499605","article-title":"Interplay Between Insulin Resistance and Immune Dysregulation in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions","volume":"14","author":"Berbudi","year":"2025","journal-title":"Immunotargets Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/emm.2016.4","article-title":"Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism","volume":"48","author":"Roh","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2008.01.050","article-title":"Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies","volume":"585","author":"Gerozissis","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ahri\u021bculesei, R.-V., Boldeanu, L., Dijm\u0103rescu, A.L., Assani, M.-Z., Boldeanu, M.V., Silo\u0219i, I., and Vere, C.C. (2025). Neurotransmitter Alterations in Prediabetes and Type 2 Diabetes Mellitus: A Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26167847"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1038\/s41591-025-03642-6","article-title":"Microbiome\u2013metabolome dynamics associated with impaired glucose control and responses to lifestyle changes","volume":"31","author":"Wu","year":"2025","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/BF03346609","article-title":"Elevated circulating free fatty acids levels causing pancreatic islet cell dysfunction through oxidative stress","volume":"33","author":"Zhang","year":"2010","journal-title":"J. Endocrinol. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"bqae044","DOI":"10.1210\/endocr\/bqae044","article-title":"\u03b2-Cell Insulin Resistance Plays a Causal Role in Fat-Induced \u03b2-Cell Dysfunction In Vitro and In Vivo","volume":"165","author":"Ivovic","year":"2024","journal-title":"Endocrinology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"114465","DOI":"10.1016\/j.celrep.2024.114465","article-title":"Excessive free fatty acid sensing in pituitary lactotrophs elicits steatotic liver disease by decreasing prolactin levels","volume":"43","author":"Ji","year":"2024","journal-title":"Cell Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.immuni.2023.05.001","article-title":"Regulation of systemic metabolism by tissue-resident immune cell circuits","volume":"56","author":"Li","year":"2023","journal-title":"Immunity"},{"key":"ref_42","unstructured":"World Health Organization (WHO)\/IDF Consultation (2006). Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia, WHO. Available online: https:\/\/www.who.int\/publications\/i\/item\/definition-and-diagnosis-of-diabetes-mellitus-and-intermediate-hyperglycaemia."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (1989). Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care, 12, 365\u2013368.","DOI":"10.2337\/diacare.12.5.365"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2337\/dc10-2377","article-title":"Glycemic Control, Complications, and Death in Older Diabetic Patients: The Diabetes and Aging Study","volume":"34","author":"Huang","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2337\/dci24-0075","article-title":"Understanding Diabetes Overtreatment in Older Adults: Are We at an Intersection?","volume":"48","author":"Bilal","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/CIRCRESAHA.120.315898","article-title":"Metabolomics and Proteomics in Type 2 Diabetes","volume":"126","author":"Chen","year":"2020","journal-title":"Circ. Res."},{"key":"ref_48","first-page":"1300","article-title":"Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes","volume":"2","author":"Mathiesen","year":"1986","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2796.1991.tb00415.x","article-title":"Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): The Stockholm Diabetes Intervention Study (SDIS) after 5 years","volume":"230","author":"Reichard","year":"1991","journal-title":"J. Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/bmj.304.6818.19","article-title":"Blood glucose concentrations and progression of diabetic retinopathy: The seven year results of the Oslo study","volume":"304","author":"Sandvik","year":"1992","journal-title":"BMJ"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"ref_53","first-page":"S266","article-title":"13. Older Adults: Standards of Care in Diabetes\u20142025","volume":"48","author":"ElSayed","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Mukonda, E., van der Westhuizen, D.J., Dave, J.A., Cleary, S., Hannan, L., Rusch, J.A., and Lesosky, M. (2025). Understanding the relationship between the frequency of HbA1c monitoring, HbA1c changes over time, and the achievement of targets: A retrospective cohort study. BMC Endocr. Disord., 25.","DOI":"10.1186\/s12902-024-01816-w"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.21037\/atm.2019.05.43","article-title":"A 7.0\u20137.7% value for glycated haemoglobin is better than a <7% value as an appropriate target for patient-centered drug treatment of type 2 diabetes mellitus","volume":"7","author":"Nunes","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/1932296820967335","article-title":"HbA1c Is Disproportionately Higher in Women and Older People With Type 1 Diabetes Compared With Flash Glucose Monitoring Metrics of Glycemic Control","volume":"16","author":"Stimson","year":"2022","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101739","DOI":"10.1016\/j.pmedr.2022.101739","article-title":"Disparities in HbA1c testing between aging US Latino and non-Latino white primary care patients","volume":"26","author":"Aceves","year":"2022","journal-title":"Prev. Med. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41591-023-02610-2","article-title":"Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A1c","volume":"29","author":"Zhou","year":"2023","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pcd.2013.01.007","article-title":"Racial differences in HbA1c: A cross-sectional analysis of a Brazilian public primary care population","volume":"7","author":"Moscavitch","year":"2013","journal-title":"Prim. Care Diabetes"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.2337\/dc15-1188","article-title":"Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis","volume":"38","author":"Gorst","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc11-s217","article-title":"Should A1C targets be individualized for all people with diabetes? Arguments for and against","volume":"34","author":"Teoh","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e002176","DOI":"10.1136\/bmjdrc-2021-002176","article-title":"Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: Implications for screening","volume":"9","author":"Anderson","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1002\/dmrr.3015","article-title":"Longitudinal trends in HbA(1c) patterns and association with outcomes: A systematic review","volume":"34","author":"Luo","year":"2018","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13098-024-01370-4","article-title":"The relationship between HbA1c control pattern and atherosclerosis progression of diabetes: A prospective study of Chinese population","volume":"16","author":"Li","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/dc10-1318","article-title":"A1C and Cardiovascular Outcomes in Type 2 Diabetes: A nested case-control study","volume":"34","author":"Colayco","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_68","first-page":"e82464","article-title":"Determinants of Poor Glycemic Control Among Type 2 Diabetes Patients: A Systematic Review","volume":"17","author":"Ahmed","year":"2025","journal-title":"Cureus"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.numecd.2017.04.009","article-title":"Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data","volume":"27","author":"Nesti","year":"2017","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: A meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/archinte.163.21.2594","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: Systematic review and meta-analysis","volume":"163","author":"Salpeter","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamainternmed.2018.0292","article-title":"Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study","volume":"178","author":"Lazarus","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_73","first-page":"H1250","article-title":"Metformin decreases plasma insulin levels and systolic blood pressure in spontaneously hypertensive rats","volume":"267","author":"Verma","year":"1994","journal-title":"Am. J. Physiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2337\/db24-0830","article-title":"Effects of Metformin on Postprandial Blood Pressure, Heart Rate, Gastric Emptying, GLP-1, and Prevalence of Postprandial Hypotension in Type 2 Diabetes: A Double-Blind Placebo-Controlled Crossover Study","volume":"74","author":"Quast","year":"2025","journal-title":"Diabetes"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Huang, K.-H., Huang, S.-W., Yang, Y., Gau, S.-Y., Tsai, T.-H., Chang, Y.-L., and Lee, C.-Y. (2025). Dose dependent relationship of metformin use and diabetic peripheral neuropathy risk in patients with type 2 diabetes mellitus. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-96445-1"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"100186","DOI":"10.1016\/j.obmed.2020.100186","article-title":"Metformin: A review of its therapeutic efficacy and adverse effects","volume":"17","author":"Shurrab","year":"2020","journal-title":"Obes. Med."},{"key":"ref_77","unstructured":"European Medicine Agency Science Medicines Health (2025, July 29). Use of Metformin to Treat Diabetes Now Expanded to Patients with Moderately Reduced Kidney Function. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/metformin-metformin-containing-medicines#topics."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/dom.15700","article-title":"Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin","volume":"26","author":"Chan","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.biochi.2012.11.004","article-title":"Vitamin B12 absorption: Mammalian physiology and acquired and inherited disorders","volume":"95","author":"Kozyraki","year":"2013","journal-title":"Biochimie"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4239\/wjd.v14.i5.585","article-title":"Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes","volume":"14","author":"Sayedali","year":"2023","journal-title":"World J. Diabetes"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clnesp.2024.04.024","article-title":"Effect of calcium supplementation on reversing metformin-based inhibition of vitamin B12 bioavailability in healthy adults using a [13C] cyanocobalamin tracer\u2014A pilot study","volume":"62","author":"Muralidharan","year":"2024","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.copbio.2020.11.001","article-title":"Understanding the impact of age-related changes in the gut microbiome on chronic diseases and the prospect of elderly-specific dietary interventions","volume":"70","author":"Pellanda","year":"2021","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"11795514221074663","DOI":"10.1177\/11795514221074663","article-title":"Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines","volume":"15","author":"Mohan","year":"2022","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40942-025-00637-w","article-title":"Impact of duration of treatments with metformin and sulfonylureas, individually or in combination, on diabetic retinopathy among newly diagnosed type 2 diabetic patients: A pooled cohort\u2019s analysis","volume":"11","author":"Bahardoust","year":"2025","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2337\/dc14-0565","article-title":"Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It\u2019s Time to Move On!","volume":"38","author":"Genuth","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0002-9343(83)90253-X","article-title":"Mechanism of action of the second-generation sulfonylurea glipizide","volume":"75","author":"Lebovitz","year":"1983","journal-title":"Am. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.diabres.2017.09.002","article-title":"New IDF clinical practice recommendations for managing type 2 diabetes in primary care","volume":"132","author":"Aschner","year":"2017","journal-title":"Diabetes Res. Clin. Pr."},{"key":"ref_88","first-page":"483","article-title":"Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records","volume":"7","author":"Kolaczynski","year":"2016","journal-title":"Diabetes Ther. Res. Treat. Educ. Diabetes Relat. Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies","volume":"40","author":"Azoulay","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"k2693","DOI":"10.1136\/bmj.k2693","article-title":"Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: Population based cohort study","volume":"362","author":"Douros","year":"2018","journal-title":"BMJ"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e026289","DOI":"10.1161\/JAHA.122.026289","article-title":"Sulfonylurea Is Associated With Higher Risks of Ventricular Arrhythmia or Sudden Cardiac Death Compared With Metformin: A Population-Based Cohort Study","volume":"11","author":"Lee","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/archinte.163.11.1306","article-title":"Clinical significance, pathogenesis, and management of postprandial hyperglycemia","volume":"163","author":"Gerich","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2337\/diacare.25.2.342","article-title":"Optimizing Insulin Secretagogue Therapy in Patients With Type 2 Diabetes: A randomized double-blind study with repaglinide","volume":"25","author":"Schmitz","year":"2002","journal-title":"Diabetes Care"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1574886315666201026125848","article-title":"Efficacy and Cardiovascular Safety of Meglitinides","volume":"16","author":"Philip","year":"2021","journal-title":"Curr. Drug Saf."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-131-4-199908170-00008","article-title":"Pharmacologic therapy for type 2 diabetes mellitus","volume":"131","author":"DeFronzo","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_96","first-page":"Cd004654","article-title":"Meglitinide analogues for type 2 diabetes mellitus","volume":"2007","author":"Black","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_97","first-page":"49","article-title":"Repaglinide in type 2 diabetes: A 24-week, fixed-dose efficacy and safety study","volume":"40","author":"Jovanovic","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","article-title":"Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study","volume":"32","author":"Schramm","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.2337\/dc05-2495","article-title":"Safety of Type 2 Diabetes Treatment With Repaglinide Compared With Glibenclamide in Elderly People: A randomized, open-label, two-period, cross-over trial","volume":"29","author":"Papa","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.diabres.2019.04.032","article-title":"Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis","volume":"152","author":"Huang","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jdiacomp.2014.11.012","article-title":"Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: A cohort study","volume":"29","author":"Huang","year":"2015","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1046\/j.1463-1326.2002.00202.x","article-title":"DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction): Theory and practice","volume":"4","author":"Davies","year":"2002","journal-title":"Diabetes Obes. Metab."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2337\/diab.45.10.1439","article-title":"Cloning, tissue expression, and chromosomal localization of SUR2, the putative drug-binding subunit of cardiac, skeletal muscle, and vascular KATP channels","volume":"45","author":"Chutkow","year":"1996","journal-title":"Diabetes"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"24321","DOI":"10.1074\/jbc.271.40.24321","article-title":"A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel","volume":"271","author":"Isomoto","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jacbts.2018.11.012","article-title":"Deletion of Sulfonylurea Receptor 2 in the Adult Myocardium Enhances Cardiac Glucose Uptake and Is Cardioprotective","volume":"4","author":"Aubert","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.hrthm.2010.06.016","article-title":"Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes","volume":"7","author":"Tan","year":"2010","journal-title":"Heart Rhythm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1042\/BST20150096","article-title":"Molecular action of sulphonylureas on KATP channels: A real partnership between drugs and nucleotides","volume":"43","author":"Proks","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1038\/s41467-022-30428-y","article-title":"Structural identification of vasodilator binding sites on the SUR2 subunit","volume":"13","author":"Ding","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.tem.2017.04.003","article-title":"Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence","volume":"28","author":"Leonard","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1161\/CIRCRESAHA.112.300514","article-title":"KATP channels and cardiovascular disease: Suddenly a syndrome","volume":"112","author":"Nichols","year":"2013","journal-title":"Circ. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11739-019-02270-6","article-title":"Biomarkers of vascular disease in diabetes: The adipose-immune system cross talk","volume":"15","author":"Biscetti","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2020.12.021","article-title":"Vascular imaging of atherosclerosis: Strengths and weaknesses","volume":"319","author":"Mantella","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","article-title":"Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes","volume":"20","author":"Soccio","year":"2014","journal-title":"Cell Metab."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2337\/diacare.28.2.488","article-title":"Thiazolidinediones","volume":"28","author":"Bloomgarden","year":"2005","journal-title":"Diabetes Care"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pds.4337","article-title":"Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study","volume":"27","author":"Leonard","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40267-024-01052-1","article-title":"What is the role of pioglitazone for patients with type 2 diabetes in value-based care settings?","volume":"40","author":"Bush","year":"2024","journal-title":"Drugs Ther. Perspect."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after Ischemic Stroke or Transient Ischemic Attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/jc.2017-01593","article-title":"Clinical Fractures Among Older Men With Diabetes Are Mediated by Diabetic Complications","volume":"103","author":"Lee","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2337\/dc12-1188","article-title":"High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: The Rotterdam Study","volume":"36","author":"Oei","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.2040-1124.2011.00142.x","article-title":"Thiazolidinediones and bone fractures","volume":"2","author":"Kaku","year":"2011","journal-title":"J. Diabetes Investig."},{"key":"ref_122","first-page":"117","article-title":"Laboratory aspects and clinical utility of bone turnover markers","volume":"29","author":"Bhattoa","year":"2018","journal-title":"Ejifcc"},{"key":"ref_123","first-page":"628628","article-title":"Thiazolidinedione-Induced Fluid Retention: Recent Insights into the Molecular Mechanisms","volume":"2013","year":"2013","journal-title":"PPAR Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.xkme.2021.07.007","article-title":"Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review","volume":"3","year":"2021","journal-title":"Kidney Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clinthera.2014.01.018","article-title":"New developments in diabetes management: Medications of the 21st century","volume":"36","author":"Fonseca","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.peptides.2017.10.011","article-title":"Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes","volume":"100","author":"Deacon","year":"2018","journal-title":"Peptides"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e151581","DOI":"10.5812\/ijpr-151581","article-title":"Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies","volume":"23","author":"Bayanati","year":"2024","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3810\/pgm.2009.01.1953","article-title":"Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice","volume":"121","author":"Bohannon","year":"2009","journal-title":"Postgrad. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diabet.2011.11.001","article-title":"DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials","volume":"38","author":"Scheen","year":"2012","journal-title":"Diabetes Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2250302","DOI":"10.1002\/eji.202250302","article-title":"Immunomodulatory activity of dipeptidyl peptidase-4 inhibitors in immune-related diseases","volume":"53","author":"Drakul","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Kawanami, D., Takashi, Y., Takahashi, H., Motonaga, R., and Tanabe, M. (2021). Renoprotective Effects of DPP-4 Inhibitors. Antioxidants, 10.","DOI":"10.3390\/antiox10020246"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"104391","DOI":"10.1016\/j.phrs.2019.104391","article-title":"More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling","volume":"147","author":"Gupta","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Huang, J., Jia, Y., Sun, S., and Meng, L. (2020). Adverse event profiles of dipeptidyl peptidase-4 inhibitors: Data mining of the public version of the FDA adverse event reporting system. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-00447-w"},{"key":"ref_136","first-page":"509","article-title":"Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes","volume":"35","author":"Pathak","year":"2010","journal-title":"Pharm. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4330\/wjc.v13.i10.585","article-title":"Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials","volume":"13","author":"Patoulias","year":"2021","journal-title":"World J. Cardiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.2337\/dcS15-3024","article-title":"Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis","volume":"39","author":"Mannucci","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"367-P","DOI":"10.2337\/db21-367-P","article-title":"367-P: Cardiovascular Risk Categories in Patients with Diabetes According to 2019 ESC\/EASD Guidelines in Clinical Practice: Use of a Dedicated App (AWARE)","volume":"70","author":"Berra","year":"2021","journal-title":"Diabetes"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/art.27395","article-title":"Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts","volume":"62","author":"Ospelt","year":"2010","journal-title":"Arthritis. Rheum."},{"key":"ref_143","first-page":"473","article-title":"DPP-4 Inhibitors Increase the Incidence of Arthritis\/Arthralgia But Do Not Affect Autoimmunity","volume":"14","author":"Sayiner","year":"2018","journal-title":"Acta. Endocrinol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.dsx.2020.12.042","article-title":"Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies","volume":"15","author":"Charoenngam","year":"2021","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_145","first-page":"223","article-title":"Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus","volume":"12","author":"Rai","year":"2019","journal-title":"Am. Health Drug Benefits"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/bcr-2018-228981","article-title":"DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis","volume":"12","author":"Padron","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_147","first-page":"100022","article-title":"Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study","volume":"2","author":"Park","year":"2021","journal-title":"Explor Res. Clin. Soc. Pharm."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2337\/dci16-0035","article-title":"DPP-4 Inhibitor\u2013Related Pancreatitis: Rare but Real!","volume":"40","author":"Rosenstock","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Wen, S., Yuan, Y., Li, Y., Xu, C., Chen, L., Ren, Y., Wang, C., He, Y., Li, X., and Gong, M. (2025). The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: A systematic review and meta-analysis of randomized clinical trials. BMC Endocr. Disord., 25.","DOI":"10.1186\/s12902-025-01985-2"},{"key":"ref_153","first-page":"383","article-title":"GLP-1 Drugs Linked to Higher Risk of Age-Related Macular Degeneration","volume":"334","author":"Anderer","year":"2025","journal-title":"JAMA"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"102475","DOI":"10.1016\/j.japh.2025.102475","article-title":"New onset diabetic retinopathy with glucagon-like peptide-1 receptor agonists: A case report","volume":"65","author":"Ko","year":"2025","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_158","first-page":"Cd015588","article-title":"Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes","volume":"5","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials","volume":"85","author":"Chen","year":"2025","journal-title":"Am. J. Kidney Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","article-title":"Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors","volume":"44","author":"Packer","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cmet.2019.08.015","article-title":"SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus","volume":"30","author":"Hess","year":"2019","journal-title":"Cell Metab."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2337\/dci24-0030","article-title":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Study: Continuing to Build on 40 Years of Diabetes Research","volume":"47","author":"Cefalu","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2337\/diaclin.22.4.162","article-title":"Effects of Glycemic Control on Diabetes Complications and on the Prevention of Diabetes","volume":"22","author":"Skyler","year":"2004","journal-title":"Clin. Diabetes"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.eprac.2025.07.014","article-title":"American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults with Dyslipidemia\u20142025 Update","volume":"31","author":"Patel","year":"2025","journal-title":"Endocr. Pract."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed, N.A., McCoy, R.G., Aleppo, G., Balapattabi, K., Beverly, E.A., Early, K.B., Bruemmer, D., Das, S.R., and Echouffo-Tcheugui, J.B. (2024). 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142025. Diabetes Care, 48, S207\u2013S238.","DOI":"10.2337\/dc25-S010"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia","volume":"31","author":"Patel","year":"2025","journal-title":"Endocr. Pr."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Li, J., Hou, D., Li, J., Li, R., and Sun, M. (2025). Association between the atherogenic index of plasma and the systemic immuno-inflammatory index using NHANES data from 2005 to 2018. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-96090-8"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Zhao, M., Xiao, M., Zhang, H., Tan, Q., Ji, J., Cheng, Y., and Lu, F. (2025). Relationship between plasma atherogenic index and incidence of cardiovascular diseases in Chinese middle-aged and elderly people. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-86213-6"},{"key":"ref_171","first-page":"e39012","article-title":"A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor","volume":"15","author":"Jeong","year":"2023","journal-title":"Cureus"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"106A","DOI":"10.1016\/j.chest.2019.02.105","article-title":"The Domino Effect: Euglycemic Diabetic Ketoacidosis From Acute Pancreatitis After Sitagliptin Use In Type 1 Diabetes Mellitus","volume":"155","author":"Lenka","year":"2019","journal-title":"CHEST"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e003666","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e2523067","DOI":"10.1001\/jamanetworkopen.2025.23067","article-title":"Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors","volume":"8","author":"Turchin","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1161\/01.CIR.103.3.369","article-title":"Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes","volume":"103","author":"Sato","year":"2001","journal-title":"Circulation"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Shomanova, Z., Ohnewein, B., Schernthaner, C., H\u00f6fer, K., Pogoda, C.A., Frommeyer, G., Wernly, B., Brandt, M.C., Dieplinger, A.M., and Reinecke, H. (2020). Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020578"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2337\/dc17-0294","article-title":"Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia","volume":"41","author":"Leonard","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/j.clinthera.2009.11.003","article-title":"The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database","volume":"31","author":"Ziyadeh","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur. J. Heart Fail"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.dsx.2015.09.016","article-title":"Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15","volume":"10","author":"Berezin","year":"2016","journal-title":"Diabetes Metab Syndr."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jchf.2014.04.005","article-title":"Sitagliptin use in patients with diabetes and heart failure: A population-based retrospective cohort study","volume":"2","author":"Weir","year":"2014","journal-title":"JACC Heart Fail"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2014.09.038","article-title":"Sitagliptin and the risk of hospitalization for heart failure: A population-based study","volume":"177","author":"Wang","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.2215\/CJN.08310520","article-title":"Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD","volume":"15","author":"Muanda","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"137","DOI":"10.59249\/NCST6937","article-title":"Natriuretic Peptides as Biomarkers: Narrative Review and Considerations in Cardiovascular and Respiratory Dysfunctions","volume":"96","author":"Samad","year":"2023","journal-title":"Yale J. Biol. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s00125-021-05557-6","article-title":"Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy","volume":"64","author":"Morgenstern","year":"2021","journal-title":"Diabetologia"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.2337\/dc13-0590","article-title":"NSE, a Potential Biomarker, Is Closely Connected to Diabetic Peripheral Neuropathy","volume":"36","author":"Li","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.2337\/db24-0365","article-title":"Effect of Metformin on Peripheral Nerve Morphology in Type 2 Diabetes: A Cross-Sectional Observational Study","volume":"73","author":"Dhanapalaratnam","year":"2024","journal-title":"Diabetes"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1111\/jgs.18397","article-title":"Association of sulfonylureas with the risk of dementia: A population-based cohort study","volume":"71","author":"Wu","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Zhang, J., Zhang, J., Zhang, C., Zhang, J., Gu, L., Luo, D., and Qiu, Q. (2022). Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells, 11.","DOI":"10.3390\/cells11213362"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The Pathobiology of Diabetic Complications: A Unifying Mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1177\/1120672120962054","article-title":"Inflammatory cytokines, oxidative and antioxidative stress levels in patients with diabetic macular edema and hyperreflective spots","volume":"31","author":"Sabaner","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"104042","DOI":"10.1016\/j.pdpdt.2024.104042","article-title":"Optical coherence tomography biomarkers indicating visual enhancement in diabetic macular edema resolved through anti-VEGF therapy: OCT biomarkers in resolved DME","volume":"46","author":"Viggiano","year":"2024","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Song, J., Chen, S., Liu, X., Duan, H., Kong, J., and Li, Z. (2015). Relationship between C-Reactive Protein Level and Diabetic Retinopathy: A Systematic Review and Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144406"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.exer.2018.07.003","article-title":"Molecular and functional characterization of circulating extracellular vesicles from diabetic patients with and without retinopathy and healthy subjects","volume":"176","author":"Mazzeo","year":"2018","journal-title":"Exp. Eye Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"78086","DOI":"10.18632\/oncotarget.17475","article-title":"Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: A nationwide, population-based study","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1007\/s00125-015-3512-0","article-title":"Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD","volume":"58","author":"Chow","year":"2015","journal-title":"Diabetologia"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"db21","DOI":"10.2337\/db21-342-P","article-title":"342-P: Effects of Sitagliptin on Hypoglycemic Episodes and Counterregulation in Type 2 Diabetic Patients Tightly Titrated with Insulin Glargine","volume":"70","author":"Nauck","year":"2021","journal-title":"Diabetes"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/dom.12833","article-title":"Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study","volume":"19","author":"Knapen","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"128","DOI":"10.18773\/austprescr.2015.043","article-title":"Blood tests for acute pancreatitis","volume":"38","author":"Basnayake","year":"2015","journal-title":"Aust. Prescr."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ccr3.83","article-title":"Sitagliptin-induced pancreatitis\u2014A longer road than expected","volume":"2","author":"Nelson","year":"2014","journal-title":"Clin. Case Rep."},{"key":"ref_202","first-page":"e7389","article-title":"Sitagliptin-induced Pancreatitis: Chronic Use Would Not Spare You the Complication","volume":"12","author":"Alkayali","year":"2020","journal-title":"Cureus"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.curtheres.2024.100737","article-title":"Biomarkers of Hepatic Toxicity: An Overview","volume":"100","author":"Thakur","year":"2024","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1871530314666141111103217","article-title":"Vitamins and type 2 diabetes mellitus","volume":"15","year":"2015","journal-title":"Endocr. Metab. Immune Disord Drug Targets"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Hannibal, L., Lysne, V., Bj\u00f8rke-Monsen, A.L., Behringer, S., Gr\u00fcnert, S.C., Spiekerkoetter, U., Jacobsen, D.W., and Blom, H.J. (2016). Biomarkers and Algorithms for the Diagnosis of Vitamin B12 Deficiency. Front. Mol. Biosci., 3.","DOI":"10.3389\/fmolb.2016.00027"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Gorgojo-Mart\u00ednez, J.J., Mezquita-Raya, P., Carretero-G\u00f3mez, J., Castro, A., Cebri\u00e1n-Cuenca, A., de Torres-S\u00e1nchez, A., Garc\u00eda-de-Lucas, M.D., N\u00fa\u00f1ez, J., Obaya, J.C., and Soler, M.J. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010145"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.cgh.2022.05.022","article-title":"Progress in Gastroparesis\u2014A Narrative Review of the Work of the Gastroparesis Clinical Research Consortium","volume":"20","author":"Pasricha","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Gong, J., Feng, Y., Mei, Y., Han, S., Sun, X., Niu, P., Tian, J., Yan, Q., Li, H., and Zhu, W. (2024). Plasma metabolomics and proteomics reveal novel molecular insights and biomarker panel for cholelithiasis. J. Pharm. Biomed. Anal., 238.","DOI":"10.1016\/j.jpba.2023.115806"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.numecd.2023.04.010","article-title":"Discordance between lipoprotein (a) and LDL-cholesterol levels in cardiovascular risk assessment in apparently healthy subjects","volume":"33","author":"Bergmann","year":"2023","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2337\/db16-0049","article-title":"Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism","volume":"65","author":"Briand","year":"2016","journal-title":"Diabetes"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.124.071269","article-title":"Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of Odyssey Outcomes","volume":"151","author":"Steg","year":"2025","journal-title":"Circulation"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e000789","DOI":"10.1136\/openhrt-2018-000789","article-title":"Is interleukin-6 the link between low LDL cholesterol and increased non-cardiovascular mortality in the elderly?","volume":"5","author":"DiNicolantonio","year":"2018","journal-title":"Open Heart"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"100344","DOI":"10.1016\/j.metop.2024.100344","article-title":"Anemia in diabetes mellitus: Pathogenetic aspects and the value of early erythropoietin therapy","volume":"25","author":"Antoniadou","year":"2025","journal-title":"Metab. Open"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/JBM.S29212","article-title":"Biomarkers for the differentiation of anemia and their clinical usefulness","volume":"4","author":"Thurnham","year":"2013","journal-title":"J. Blood Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"e2517086","DOI":"10.1001\/jamanetworkopen.2025.17086","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes","volume":"8","author":"Lewis","year":"2025","journal-title":"JAMA Netw. Open."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1182\/blood-2024-207610","article-title":"Effect of SGLT2 Inhibitors on Erythrocytosis and Arterial Thrombosis Risk in Patients with Type 2 Diabetes Mellitus: A Real-World Multi-Center Cohort Study across the United States","volume":"144","author":"Chen","year":"2024","journal-title":"Blood"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00125-023-05876-w","article-title":"Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: A randomised trial","volume":"66","author":"Gullaksen","year":"2023","journal-title":"Diabetologia"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/asheducation-2005.1.195","article-title":"A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases","volume":"2005","author":"Vainchenker","year":"2005","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"23247096221111774","DOI":"10.1177\/23247096221111774","article-title":"Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy","volume":"10","author":"Schumacher","year":"2022","journal-title":"J. Investig. Med. High Impact. Case Rep."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.ajkd.2024.02.015","article-title":"Erythrocytosis and CKD: A Review","volume":"84","author":"Aoun","year":"2024","journal-title":"Am. J. Kidney Dis."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.anai.2022.08.735","article-title":"The First Report Of Angioedema And Anaphylaxis With Temporal Association To Semaglutide","volume":"129","author":"Feinstein","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.jaci.2017.07.012","article-title":"Cleaved kininogen as a biomarker for bradykinin release in hereditary angioedema","volume":"140","author":"Hofman","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","article-title":"The International\/Canadian Hereditary Angioedema Guideline","volume":"15","author":"Betschel","year":"2019","journal-title":"Allergy Asthma. Clin. Immunol."},{"key":"ref_226","first-page":"e30077","article-title":"A Rare Case Report of Sitagliptin-Induced Angioedema","volume":"14","author":"Sharma","year":"2022","journal-title":"Cureus"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2213-8587(19)30382-1","article-title":"Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: A pharmacovigilance analysis","volume":"8","author":"Pradhan","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fimmu.2019.00494","article-title":"Biomarkers in Human Anaphylaxis: A Critical Appraisal of Current Evidence and Perspectives","volume":"10","author":"Beck","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"712","DOI":"10.2337\/dc23-1911","article-title":"Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study","volume":"47","author":"Anthony","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Saini, K., Sharma, S., and Khan, Y. (2023). DPP-4 inhibitors for treating T2DM-hype or hope? an analysis based on the current literature. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1130625"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40842-024-00165-w","article-title":"Dermatological side effects of dipeptidyl Peptidase-4 inhibitors in diabetes management: A comprehensive review","volume":"10","author":"Zaresharifi","year":"2024","journal-title":"Clin. Diabetes Endocrinol."},{"key":"ref_232","unstructured":"Prescribing Information (2006). JANUVIA (Sitagliptin), Merck."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Williams-Herman, D., Round, E., Swern, A.S., Musser, B., Davies, M.J., Stein, P.P., Kaufman, K.D., and Amatruda, J.M. (2008). Safety and tolerability of sitagliptin in patients with type 2 diabetes: A pooled analysis. BMC Endocr. Disord., 8.","DOI":"10.1186\/1472-6823-8-14"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1398-9995.2010.02484.x","article-title":"Expression of \u03b1-defensin 1\u20133 in T cells from severe cutaneous drug-induced hypersensitivity reactions","volume":"66","author":"Morel","year":"2011","journal-title":"Allergy"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"eaax2398","DOI":"10.1126\/scitranslmed.aax2398","article-title":"Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"13","author":"Kinoshita","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1097\/CM9.0000000000003250","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management","volume":"137","author":"Hasegawa","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"100054","DOI":"10.1016\/j.gmg.2025.100054","article-title":"A review of the immunogenetics of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"12","author":"Kocaaga","year":"2025","journal-title":"Glob. Med. Genet."},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Vuj\u010di\u0107, S., Kotur-Stevuljevi\u0107, J., Veki\u0107, J., Perovi\u0107-Blagojevi\u0107, I., Stefanovi\u0107, T., Ili\u0107-Mijailovi\u0107, S., Koprivica Uzelac, B., Bosi\u0107, S., Antoni\u0107, T., and Guzonji\u0107, A. (2022). Oxidative Stress and Inflammatory Biomarkers in Patients with Diabetic Foot. Medicina, 58.","DOI":"10.3390\/medicina58121866"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.paed.2019.01.007","article-title":"\u2018Ammonia, lactate and blood gases\u2014A user\u2019s guide\u2019","volume":"29","author":"Davison","year":"2019","journal-title":"Paediatr. Child. Health"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: Current perspectives on causes and risk","volume":"65","author":"Fleming","year":"2016","journal-title":"Metabolism"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin. Pharmacokinet"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Yang, H., Dai, H., Chen, X., Huang, J., Miao, F., Lv, J., and Zhang, J. (2025). Risk of medication-induced lactic acidosis and hyperlactatemia: A pharmacovigilance study of the United States Food and Drug Administration\u2019s Adverse Event Reporting System database. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1555955"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.4239\/wjd.v15.i6.1178","article-title":"Metformin-associated lactic acidosis: A mini review of pathophysiology, diagnosis and management in critically ill patients","volume":"15","author":"See","year":"2024","journal-title":"World J. Diabetes"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1111\/dom.15110","article-title":"Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan","volume":"25","author":"Smeijer","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/apha.12054","article-title":"Neutrophil gelatinase-associated lipocalin: Pathophysiology and clinical applications","volume":"207","author":"Singer","year":"2013","journal-title":"Acta Physiol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"e127456","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-\u03b1 and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13613-024-01360-9","article-title":"Biomarkers in acute kidney injury","volume":"14","author":"Ostermann","year":"2024","journal-title":"Ann. Intensive Care"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"F1472","DOI":"10.1152\/ajprenal.00619.2009","article-title":"Transcriptional analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of AKI-to-CKD transition","volume":"298","author":"Ko","year":"2010","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/dom.15991","article-title":"Key biomarkers in type 2 diabetes patients: A systematic review","volume":"27","author":"Le","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1917","article-title":"Interleukin-6 and chronic inflammation","volume":"8","author":"Gabay","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_254","unstructured":"Singh, B., Goyal, A., and Patel, B.C. (2025). C-Reactive Protein: Clinical Relevance and Interpretation. StatPearls, StatPearls Publishing LLC."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0090-1229(88)90160-2","article-title":"Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle","volume":"48","author":"Rees","year":"1988","journal-title":"Clin. Immunol. Immunopathol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1161\/01.CIR.0000146846.00816.DD","article-title":"Opposing Effects of C-Reactive Protein Isoforms on Shear-Induced Neutrophil-Platelet Adhesion and Neutrophil Aggregation in Whole Blood","volume":"110","author":"Khreiss","year":"2004","journal-title":"Circulation"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/CIRCRESAHA.108.190611","article-title":"Dissociation of Pentameric to Monomeric C-Reactive Protein on Activated Platelets Localizes Inflammation to Atherosclerotic Plaques","volume":"105","author":"Eisenhardt","year":"2009","journal-title":"Circ. Res."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1096\/fj.08-116962","article-title":"Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains","volume":"23","author":"Ji","year":"2009","journal-title":"FASEB J."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12933-023-01979-1","article-title":"Inflammation and oxidative stress markers in type 2 diabetes patients with Advanced Carotid atherosclerosis","volume":"22","author":"Laubriet","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"ref_260","first-page":"Bc01","article-title":"A Comparative Study of High Sensitivity C-Reactive Protein and Metabolic Variables in Type 2 Diabetes Mellitus with and without Nephropathy","volume":"11","author":"Shaheer","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_261","doi-asserted-by":"crossref","unstructured":"Ghiasi Hafezi, S., Sahranavard, T., Kooshki, A., Hosseini, M., Mansoori, A., Fakhrian, E.A., Rezaeifard, H., Ghamsary, M., Esmaily, H., and Ghayour-Mobarhan, M. (2024). Predicting high sensitivity C-reactive protein levels and their associations in a large population using decision tree and linear regression. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-81714-2"},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Bowker, N., Shah, R.L., Sharp, S.J., Luan, J.a., Stewart, I.D., Wheeler, E., Ferreira, M.A.R., Baras, A., Wareham, N.J., and Langenberg, C. (2020). Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes. eBioMedicine, 61.","DOI":"10.1016\/j.ebiom.2020.103062"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00125-009-1338-3","article-title":"Association of C-reactive protein with type 2 diabetes: Prospective analysis and meta-analysis","volume":"52","author":"Lee","year":"2009","journal-title":"Diabetologia"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.placenta.2021.02.021","article-title":"Effect of metformin on biomarkers of placental- mediated disease: A systematic review and meta-analysis","volume":"107","author":"Anness","year":"2021","journal-title":"Placenta"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diabres.2018.04.041","article-title":"White blood cells count as an indicator to identify whether obesity leads to increased risk of type 2 diabetes","volume":"141","author":"Gu","year":"2018","journal-title":"Diabetes Res. Clin. Pr."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"50835","DOI":"10.18632\/oncotarget.10615","article-title":"Leukocyte telomere length and mortality risk in patients with type 2 diabetes","volume":"7","author":"Bonfigli","year":"2016","journal-title":"Oncotarget"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"50835","DOI":"10.3390\/cells11121979","article-title":"The Good and the Bad: Monocytes\u2019 and Macrophages\u2019 Diverse Functions in Inflammation","volume":"11","author":"Austermann","year":"2022","journal-title":"Cells"},{"key":"ref_268","doi-asserted-by":"crossref","unstructured":"Chandrasekaran, P., and Weiskirchen, R. (2024). The Role of Obesity in Type 2 Diabetes Mellitus-An Overview. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031882"},{"key":"ref_269","doi-asserted-by":"crossref","unstructured":"Wang, D., Chen, F., Han, Z., Yin, Z., Ge, X., and Lei, P. (2021). Relationship Between Amyloid-\u03b2 Deposition and Blood\u2013Brain Barrier Dysfunction in Alzheimer\u2019s Disease. Front. Cell. Neurosci., 15.","DOI":"10.3389\/fncel.2021.695479"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41577-021-00635-7","article-title":"Immune and non-immune functions of adipose tissue leukocytes","volume":"22","author":"Trim","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2021.12.012","article-title":"Metabolic adaptation of lymphocytes in immunity and disease","volume":"55","author":"Chapman","year":"2022","journal-title":"Immunity"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1568010023344535","article-title":"TNFalpha as therapeutic target: New drugs, more applications","volume":"1","author":"Reimold","year":"2002","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1212\/WNL.0000000000200521","article-title":"Determining Vascular Risk Factors for Dementia and Dementia Risk Prediction Across Mid- to Later Life: The Framingham Heart Study","volume":"99","author":"McGrath","year":"2022","journal-title":"Neurology"},{"key":"ref_276","doi-asserted-by":"crossref","unstructured":"Ikram, M.A., Bersano, A., Manso-Calder\u00f3n, R., Jia, J.P., Schmidt, H., Middleton, L., Nacmias, B., Siddiqi, S., and Adams, H.H. (2017). Genetics of vascular dementia\u2014Review from the ICVD working group. BMC Med., 15.","DOI":"10.1186\/s12916-017-0813-9"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12986-024-00880-2","article-title":"Foods, dietary patterns, and risk of vascular dementia: A systematic review","volume":"21","author":"Griffiths","year":"2024","journal-title":"Nutr. Metab."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"e030780","DOI":"10.1161\/JAHA.123.030780","article-title":"Cardiovascular Disease and Alzheimer\u2019s Disease: The Heart\u2014Brain Axis","volume":"12","author":"Saeed","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_279","doi-asserted-by":"crossref","unstructured":"Han, S., Lelieveldt, T., Sturkenboom, M., Biessels, G.J., and Ahmadizar, F. (2025). Evaluating the Causal Association Between Type 2 Diabetes and Alzheimer\u2019s Disease: A Two-Sample Mendelian Randomization Study. Biomedicines, 13.","DOI":"10.3390\/biomedicines13051095"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3233\/ADR-240053","article-title":"Causal Association Between Type 2 Diabetes Mellitus and Alzheimer\u2019s Disease: A Two-Sample Mendelian Randomization Study","volume":"8","author":"Li","year":"2024","journal-title":"J. Alzheimers. Dis. Rep."},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Bender, E.C., Tareq, H.S., and Suggs, L.J. (2025). Inflammation: A matter of immune cell life and death. npj Biomed. Innov., 2.","DOI":"10.1038\/s44385-025-00010-4"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","article-title":"Parkinson disease and the immune system\u2014Associations, mechanisms and therapeutics","volume":"16","author":"Tan","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Wang, W., and Lo, A.C.Y. (2018). Diabetic Retinopathy: Pathophysiology and Treatments. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061816"},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Al-Shabrawey, M., Zhang, W., and McDonald, D. (2015). Diabetic retinopathy: Mechanism, diagnosis, prevention, and treatment. Biomed Res. Int., 2015.","DOI":"10.1155\/2015\/854593"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"H153","DOI":"10.1152\/ajpheart.00206.2015","article-title":"Damaging effects of hyperglycemia on cardiovascular function: Spotlight on glucose metabolic pathways","volume":"310","author":"Mapanga","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"101515","DOI":"10.1016\/j.molmet.2022.101515","article-title":"Advances in the study of RNA-binding proteins in diabetic complications","volume":"62","author":"Chen","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"e93751","DOI":"10.1172\/jci.insight.93751","article-title":"Diabetic retinopathy: Current understanding, mechanisms, and treatment strategies","volume":"2","author":"Duh","year":"2017","journal-title":"JCI Insight"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s13167-023-00314-8","article-title":"Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation","volume":"14","author":"Kropp","year":"2023","journal-title":"Epma J."},{"key":"ref_289","doi-asserted-by":"crossref","unstructured":"Baumal, C.R., and Duker, J.S. (2018). Chapter 5\u2014Genetics of Diabetic Retinopathy. Current Management of Diabetic Retinopathy, Elsevier.","DOI":"10.1016\/B978-0-323-48452-7.00004-4"},{"key":"ref_290","first-page":"e52308","article-title":"A Narrative Review of Retinopathy in Diabetic Patients","volume":"16","author":"Gupta","year":"2024","journal-title":"Cureus"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"e162632","DOI":"10.1172\/jci.insight.162632","article-title":"PGC-1\u03b1\u2013mediated angiogenesis prevents pulmonary hypertension in mice","volume":"8","author":"Fujiwara","year":"2023","journal-title":"JCI Insight"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ijcard.2015.03.353","article-title":"Estrogen-Related Receptor \u03b1 (ERR\u03b1) is required for adaptive increases in PGC-1 isoform expression during electrically stimulated contraction of adult cardiomyocytes in sustained hypoxic conditions","volume":"187","author":"Cunningham","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1161\/ATVBAHA.108.181636","article-title":"Regulation of Hypoxia-Inducible Genes by PGC-1\u03b1","volume":"30","author":"Shoag","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1073\/pnas.0401420101","article-title":"Regulation of PPAR\u03b3 coactivator 1\u03b1 (PGC-1\u03b1) signaling by an estrogen-related receptor \u03b1 (ERR\u03b1) ligand","volume":"101","author":"Willy","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"1615103","DOI":"10.3389\/fendo.2025.1615103","article-title":"A key role of the PGC-1alpha\/ERR-alpha pathway in regulation of angiogenic factors in proliferative diabetic retinopathy","volume":"16","author":"Nawaz","year":"2025","journal-title":"Front. Endocrinol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1442-9071.2006.01437.x","article-title":"Erythropoietin levels in aqueous humour in eyes with exudative age-related macular degeneration and diabetic retinopathy","volume":"35","author":"Jonas","year":"2007","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4103\/npmj.npmj_127_25","article-title":"An Assessment of Serum Irisin and Intercellular Adhesion Molecule-1 as Potential Indicators of Retinopathy in Type 2 Diabetes Mellitus","volume":"32","author":"Sherwin","year":"2025","journal-title":"Niger. Postgrad. Med. J."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/tvst.14.7.27","article-title":"Postprandial C-Peptide to Glucose Ratio as a Promising Systemic Marker of Diabetic Retinopathy in Type 2 Diabetes","volume":"14","author":"Zheng","year":"2025","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.18240\/ijo.2025.08.12","article-title":"Combination of red blood cell distribution width and platelet-to-lymphocyte ratio for predicting severity of diabetic retinopathy","volume":"18","author":"Wei","year":"2025","journal-title":"Int. J. Ophthalmol."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12933-025-02899-y","article-title":"Unveiling biomarkers via plasma metabolome profiling for diabetic macrovascular and microvascular complications","volume":"24","author":"Li","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"100870","DOI":"10.1016\/j.xops.2025.100870","article-title":"Plasma Sphingomyelins as Biomarkers for Diabetic Retinal Neurodegeneration: The Maastricht Study","volume":"5","author":"Jadhav","year":"2025","journal-title":"Ophthalmol. Sci."},{"key":"ref_302","doi-asserted-by":"crossref","unstructured":"Hao, Y., She, X., Huang, G., Chu, X., Zhao, S., Lv, Z., Tao, J., and Zhang, Y. (2025). Metabolomic insights into vitreous humor with therapy outcome in type 2 diabetic retinopathy. BMC Ophthalmol., 25.","DOI":"10.1186\/s12886-025-04283-6"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"11795514251365301","DOI":"10.1177\/11795514251365301","article-title":"Novel Lipid Biomarkers and Microvascular Complications in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis","volume":"18","author":"Zooravar","year":"2025","journal-title":"Clin. Med. Insights Endocrinol Diabetes"},{"key":"ref_304","doi-asserted-by":"crossref","unstructured":"Cao, D., Yang, Q., Hong, Y., Tan, R., Ibrahim, F.N.I., Lim, C., Choo, J., Sabanayagam, C., Coffman, T.M., and Wong, T.Y. (2025). Retinal Neuronal Changes and Kidney Dysfunction in Diabetes Mellitus. Clin. Exp. Ophthalmol., 1\u201313.","DOI":"10.1111\/ceo.14592"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"7934504","DOI":"10.1155\/2016\/7934504","article-title":"A Systems Biology Overview on Human Diabetic Nephropathy: From Genetic Susceptibility to Post-Transcriptional and Post-Translational Modifications","volume":"2016","author":"Conserva","year":"2016","journal-title":"J. Diabetes Res."},{"key":"ref_306","doi-asserted-by":"crossref","unstructured":"Childs, B.P., Cypress, M., and Spollett, G.R. (2017). Diabetic Nephropathy and End-Stage Renal Disease. Complete Nurse\u2019s Guide to Diabetes Care, American Diabetes Association.","DOI":"10.2337\/9781580405690"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2337\/db20211-2","article-title":"Pathogenesis of Diabetic Nephropathy","volume":"2021","author":"Agarwal","year":"2021","journal-title":"Compendia"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4062\/biomolther.2020.204","article-title":"Diabetic Nephropathy\u2014A Review of Risk Factors, Progression, Mechanism, and Dietary Management","volume":"29","author":"Natesan","year":"2021","journal-title":"Biomol. Ther."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0002-9343(82)90490-9","article-title":"The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies","volume":"72","author":"Hostetter","year":"1982","journal-title":"Am. J. Med."},{"key":"ref_310","doi-asserted-by":"crossref","unstructured":"Wu, T., Ding, L., Andoh, V., Zhang, J., and Chen, L. (2023). The Mechanism of Hyperglycemia-Induced Renal Cell Injury in Diabetic Nephropathy Disease: An Update. Life, 13.","DOI":"10.3390\/life13020539"},{"key":"ref_311","doi-asserted-by":"crossref","unstructured":"Yin, R., Zhang, Y., Fang, X., Zhang, Y., Miao, R., Yao, Y., Guan, H., and Tian, J. (2025). Discovering diabetes complications-related microRNAs: Meta-analyses and pathway modeling approach. BMC Med. Genom., 18.","DOI":"10.1186\/s12920-025-02144-1"},{"key":"ref_312","first-page":"9793","article-title":"Circulating hsa-miR-221 as a possible diagnostic and prognostic biomarker of diabetic nephropathy","volume":"50","author":"Mohamed","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/etm.2024.12785","article-title":"Integrated analysis of long non-coding RNA megacluster, microRNA-132 and microRNA-133a and their implications for cardiovascular risk and kidney failure progression in diabetic patients","volume":"29","author":"Abdelgayed","year":"2025","journal-title":"Exp. Ther. Med."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ahj.2024.02.016","article-title":"Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial","volume":"271","author":"Januzzi","year":"2024","journal-title":"Am. Heart J."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00125-012-2737-4","article-title":"Adipocyte fatty acid binding protein: A novel adipokine involved in the pathogenesis of metabolic and vascular disease?","volume":"56","author":"Kralisch","year":"2013","journal-title":"Diabetologia"},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"E292","DOI":"10.1152\/ajpendo.00101.2017","article-title":"Fibroblast growth factor 21: A regulator of metabolic disease and health span","volume":"313","author":"Xie","year":"2017","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.biochi.2022.05.019","article-title":"Pigment epithelium-derived factor and its role in microvascular-related diseases","volume":"200","author":"Wang","year":"2022","journal-title":"Biochimie"},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/db18-0500","article-title":"Genetic Regulation of Pigment Epithelium-Derived Factor (PEDF): An Exome-Chip Association Analysis in Chinese Subjects With Type 2 Diabetes","volume":"68","author":"Cheung","year":"2018","journal-title":"Diabetes"},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12933-025-02830-5","article-title":"A scoring model integrating CXCL9, GDF15, FGF21, and NfL, predicts long-term mortality in type 2 diabetes: A retrospective study","volume":"24","author":"Sbriscia","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/dom.16066","article-title":"Circulating inflammatory proteins are elevated in type 1 and type 2 diabetes and associated to complications","volume":"27","author":"Ajie","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_321","doi-asserted-by":"crossref","unstructured":"AlMajed, H.T., Abu-Farha, M., Alshawaf, E., Devarajan, S., Alsairafi, Z., Elhelaly, A., Cherian, P., Al-Khairi, I., Ali, H., and Jose, R.M. (2023). Increased Levels of Circulating IGFBP4 and ANGPTL8 with a Prospective Role in Diabetic Nephropathy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814244"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11255-024-04179-2","article-title":"Role of GDF-15 in diabetic nephropathy: Mechanisms, diagnosis, and therapeutic potential","volume":"57","author":"Zhang","year":"2025","journal-title":"Int. Urol. Nephrol."},{"key":"ref_323","doi-asserted-by":"crossref","unstructured":"Hou, Q., Huang, K., Liang, Y., Yu, W., Long, L., Wang, K., and Yi, B. (2025). Associations between serum JAML, nesfatin-1, and 25(OH)D and the risk of diabetic kidney disease in patients with type 2 diabetes. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-12941-4"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.freeradbiomed.2023.12.025","article-title":"Serum peroxiredoxin-4, a biomarker of oxidative stress, is associated with the development of nephropathy in patients with type 2 diabetes (Zodiac-65)","volume":"212","author":"Bourgonje","year":"2024","journal-title":"Free Radic. Biol. Med."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40200-022-01152-7","article-title":"Diagnostic values of ischemia modified albumin in diabetes-related complications: A narrative review","volume":"22","author":"Ghareghani","year":"2023","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"103722","DOI":"10.1016\/j.numecd.2024.08.015","article-title":"8-hydroxy-2\u2032-deoxyguanosine, a biomarker of oxidative DNA injury, in diabetic kidney disease","volume":"35","author":"Spoto","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"110900","DOI":"10.1016\/j.diabres.2023.110900","article-title":"The potential of cardiac biomarkers, NT-ProBNP and troponin T, in predicting the progression of nephropathy in diabetic patients: A meta-analysis of prospective cohort studies","volume":"204","author":"Roointan","year":"2023","journal-title":"Diabetes Res. Clin. Pr."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.2040-1124.2010.00070.x","article-title":"Mechanism of diabetic neuropathy: Where are we now and where to go?","volume":"2","author":"Yagihashi","year":"2011","journal-title":"J. Diabetes Investig."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2337\/db19-0321","article-title":"Brain and Body: A Review of Central Nervous System Contributions to Movement Impairments in Diabetes","volume":"69","author":"Ferris","year":"2019","journal-title":"Diabetes"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/dc14-1196","article-title":"Spatial patterns of structural brain changes in type 2 diabetic patients and their longitudinal progression with intensive control of blood glucose","volume":"38","author":"Erus","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s13340-019-00424-7","article-title":"Spectrum of diabetic neuropathies","volume":"11","author":"Sasaki","year":"2020","journal-title":"Diabetol. Int."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1111\/jdi.13691","article-title":"Autonomic dysfunction, diabetes and metabolic syndrome","volume":"12","author":"Yu","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4239\/wjd.v9.i1.1","article-title":"Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment","volume":"9","author":"Serhiyenko","year":"2018","journal-title":"World J. Diabetes"},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jns.12424","article-title":"Small and large fiber sensory polyneuropathy in type 2 diabetes: Influence of diagnostic criteria on neuropathy subtypes","volume":"26","author":"Itani","year":"2021","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"e70094","DOI":"10.1111\/1753-0407.70094","article-title":"Plantar Tissue Characteristics in People With Diabetes With and Without Peripheral Neuropathy: A Novel Explanatory Model for DPN Risk Assessment","volume":"17","author":"Li","year":"2025","journal-title":"J. Diabetes"},{"key":"ref_336","first-page":"e14302","article-title":"Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes","volume":"75","author":"Ascaso","year":"2021","journal-title":"Int. J. Clin. Pr."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/jdi.14197","article-title":"Circulating netrin-1 levels are reduced and related to corneal nerve fiber loss in patients with diabetic neuropathy","volume":"15","author":"Mondal","year":"2024","journal-title":"J. Diabetes Investig."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1042\/BCJ20160082","article-title":"Ubiquitin C-terminal hydrolase L1 (UCH-L1): Structure, distribution and roles in brain function and dysfunction","volume":"473","author":"Bishop","year":"2016","journal-title":"Biochem. J."},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00592-025-02500-8","article-title":"Glial fibrillary acidic protein: A potential biomarker for small fiber neuropathy?","volume":"62","author":"Hviid","year":"2025","journal-title":"Acta. Diabetol."},{"key":"ref_341","doi-asserted-by":"crossref","unstructured":"Khalid, M., Petroianu, G., and Adem, A. (2022). Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules, 12.","DOI":"10.3390\/biom12040542"},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s10020-024-00905-9","article-title":"Advanced glycation end products and reactive oxygen species: Uncovering the potential role of ferroptosis in diabetic complications","volume":"30","author":"Chen","year":"2024","journal-title":"Mol. Med."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jdiacomp.2017.10.004","article-title":"Circulating levels of Hsp27 in microvascular complications of diabetes: Prospects as a biomarker of diabetic nephropathy","volume":"32","author":"Jakhotia","year":"2018","journal-title":"J. Diabetes Complicat."},{"key":"ref_344","doi-asserted-by":"crossref","unstructured":"Matuschik, L., Riabov, V., Schmuttermaier, C., Sevastyanova, T., Weiss, C., Kl\u00fcter, H., and Kzhyshkowska, J. (2022). Hyperglycemia Induces Inflammatory Response of Human Macrophages to CD163-Mediated Scavenging of Hemoglobin-Haptoglobin Complexes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031385"},{"key":"ref_345","doi-asserted-by":"crossref","unstructured":"Le Jeune, S., Sadoudi, S., Charue, D., Abid, S., Guigner, J.M., Helley, D., Bihan, H., Baudry, C., Lelong, H., and Mirault, T. (2022). Low grade intravascular hemolysis associates with peripheral nerve injury in type 2 diabetes. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0275337"},{"key":"ref_346","doi-asserted-by":"crossref","unstructured":"Wang, M. (2020). Coronary Artery Disease: From Mechanism to Clinical Practice. Coronary Artery Disease: Therapeutics and Drug Discovery, Springer.","DOI":"10.1007\/978-981-15-2517-9"},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s43856-025-00785-y","article-title":"Identifying and ranking non-traditional risk factors for cardiovascular disease prediction in people with type 2 diabetes","volume":"5","author":"Dziopa","year":"2025","journal-title":"Commun Med."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/1573402110666140702091315","article-title":"Dyslipidemia, Hypertension and Diabetes Metaflammation. A Unique Mechanism for 3 Risk Factors","volume":"9","year":"2014","journal-title":"Curr. Hypertens Rev."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/0735-1097(92)90033-J","article-title":"Acute myocardial infarction in the diabetic patient: Pathophysiology, clinical course and prognosis","volume":"20","author":"Jacoby","year":"1992","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_350","doi-asserted-by":"crossref","unstructured":"Karakasis, P., Theofilis, P., Patoulias, D., Vlachakis, P.K., Antoniadis, A.P., and Fragakis, N. (2025). Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26052196"},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"e021660","DOI":"10.1161\/JAHA.121.021660","article-title":"Coronary Artery Disease and Heart Failure With Preserved Ejection Fraction: The ARIC Study","volume":"11","author":"John","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1161\/CIRCULATIONAHA.113.001258","article-title":"Unstable Angina","volume":"127","author":"Braunwald","year":"2013","journal-title":"Circulation"},{"key":"ref_353","unstructured":"Levine, G.N. (2018). Chapter 15\u2014Chronic Stable Angina. Cardiology Secrets, Elsevier. [5th ed.]."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"Jama"},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"e041223","DOI":"10.1161\/JAHA.124.041223","article-title":"Modifiable Factors and 10-Year and Lifetime Risk of Cardiovascular Disease in Adults With New-Onset Diabetes: The Kailuan Cohort Study","volume":"14","author":"Wu","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_356","doi-asserted-by":"crossref","unstructured":"Jasaszwili, M., Billert, M., Strowski, M.Z., Nowak, K.W., and Skrzypski, M. (2020). Adropin as A Fat-Burning Hormone with Multiple Functions-Review of a Decade of Research. Molecules, 25.","DOI":"10.3390\/molecules25030549"},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"H238","DOI":"10.1152\/ajpheart.00449.2020","article-title":"Adropin: A hepatokine modulator of vascular function and cardiac fuel metabolism","volume":"320","author":"Mushala","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_358","doi-asserted-by":"crossref","unstructured":"Berezina, T.A., Berezin, O.O., Novikov, E.V., and Berezin, A.E. (2025). The Association of Adropin with Asymptomatic Coronary Calcification in Patients in Early Stages of Chronic Kidney Disease. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202506.1964.v1"},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"993","DOI":"10.4093\/dmj.2023.0410","article-title":"Prognostic Value of Plasma Endothelin-1 in Predicting Worse Outcomes in Patients with Prediabetes and Diabetes and Stable Coronary Artery Diseases","volume":"48","author":"Yang","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"ref_360","doi-asserted-by":"crossref","unstructured":"Boieriu, A.M., Luca, C.D., Neculoiu, C.D., Bisoc, A., and Tint, D. (2025). Endothelial Dysfunction and Oxidative Stress in Patients with Severe Coronary Artery Disease: Does Diabetes Play a Contributing Role?. Medicina, 61.","DOI":"10.3390\/medicina61010135"},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacasi.2023.01.004","article-title":"Ischemia With Nonobstructive Coronary Artery Disease","volume":"3","author":"Hwang","year":"2023","journal-title":"JACC Asia"},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12933-024-02331-x","article-title":"Endothelial microRNAs in INOCA patients with diabetes mellitus","volume":"23","author":"Ferrone","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamacardio.2025.0945","article-title":"Epidemiological and Translational Study of Calprotectin and Atherosclerotic Cardiovascular Disease","volume":"10","author":"Zuo","year":"2025","journal-title":"JAMA Cardiol."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/rheumatology\/kead405","article-title":"Calprotectin: Two sides of the same coin","volume":"63","author":"Carnazzo","year":"2024","journal-title":"Rheumatology"},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"132698","DOI":"10.1016\/j.ijcard.2024.132698","article-title":"Lipoproteins and lipoprotein lipid composition are associated with stages of dysglycemia and subclinical coronary atherosclerosis","volume":"419","author":"Gigante","year":"2025","journal-title":"Int. J. Cardiol."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12933-025-02624-9","article-title":"Inverse relationship between circulating sphingosine-1-phosphate and precursor species and coronary artery calcification score in type 2 diabetes","volume":"24","author":"Bourron","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"110040","DOI":"10.1016\/j.diabres.2022.110040","article-title":"Association between circulating oxidized OxLDL\/LDL-C ratio and the severity of coronary atherosclerosis, along with other emerging biomarkers of cardiovascular disease in patients with type 2 diabetes","volume":"191","author":"Xu","year":"2022","journal-title":"Diabetes Res. Clin. Pr."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/joim.12400","article-title":"The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosis","volume":"278","author":"Chakravarti","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_369","first-page":"2350","article-title":"Correlation between the serum lumican level and the severity of coronary artery disease","volume":"27","author":"Kirankaya","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12933-024-02466-x","article-title":"The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease","volume":"23","author":"Hershenson","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s40200-023-01305-2","article-title":"Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: A post-hoc analysis of EMPA-CARD Trial","volume":"22","author":"Taheri","year":"2023","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_372","doi-asserted-by":"crossref","unstructured":"Jin, Q., and Ma, R.C.W. (2021). Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies. Cells, 10.","DOI":"10.3390\/cells10112832"},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"102158","DOI":"10.1155\/2014\/102158","article-title":"Diabetes and the brain: Oxidative stress, inflammation, and autophagy","volume":"2014","author":"Muriach","year":"2014","journal-title":"Oxid Med. Cell Longev."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00125-019-4959-1","article-title":"New insights into the mechanisms of diabetic complications: Role of lipids and lipid metabolism","volume":"62","author":"Eid","year":"2019","journal-title":"Diabetologia"},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1016\/j.celrep.2018.05.010","article-title":"Obesity and Insulin Resistance Promote Atherosclerosis through an IFN\u03b3\u2014Regulated Macrophage Protein Network","volume":"23","author":"Reardon","year":"2018","journal-title":"Cell Rep."},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"1092431","DOI":"10.3389\/fendo.2022.1092431","article-title":"Insulin resistance in ischemic stroke: Mechanisms and therapeutic approaches","volume":"13","author":"Ding","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.cmet.2025.04.009","article-title":"The foam cell-derived exosomes exacerbate ischemic white matter injury via transmitting metabolic defects to microglia","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell Metab."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.120.046464","article-title":"Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis","volume":"144","author":"Edgar","year":"2021","journal-title":"Circulation"},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"e213480","DOI":"10.1212\/WNL.0000000000213480","article-title":"Risk of Ischemic and Hemorrhagic Stroke in Individuals With Type 1 and Type 2 Diabetes: A Nationwide Cohort Study in Sweden","volume":"104","author":"Mavridis","year":"2025","journal-title":"Neurology"},{"key":"ref_380","doi-asserted-by":"crossref","unstructured":"Dogan, Z., Senyigit, A., Durmus, S., Duvarci, C., Gelisgen, R., Uzun, H., and Tabak, O. (2025). The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-89220-9"},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"190143","DOI":"10.1183\/16000617.0143-2019","article-title":"Chitotriosidase: A marker and modulator of lung disease","volume":"29","author":"Chang","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1161\/01.ATV.0000089329.09061.07","article-title":"Serum Chitotriosidase Activity Is Increased in Subjects With Atherosclerosis Disease","volume":"23","author":"Artieda","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_383","doi-asserted-by":"crossref","unstructured":"Cerqueira, A., Quelhas-Santos, J., Ferreira, I., Sampaio, S., Relvas, M., Marques, N., Dias, C.C., and Pestana, M. (2021). Circulating Renalase as Predictor of Renal and Cardiovascular Outcomes in Pre-Dialysis CKD Patients: A 5-Year Prospective Cohort Study. Life, 11.","DOI":"10.3390\/life11030210"},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1210\/er.2013-1079","article-title":"Molecular basis of Klotho: From gene to function in aging","volume":"36","author":"Xu","year":"2015","journal-title":"Endocr. Rev."},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2018.07.006","article-title":"Circulating Klotho levels can predict long-term macrovascular outcomes in type 2 diabetic patients","volume":"276","author":"Pan","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_386","first-page":"1234","article-title":"Number and function of circulating endothelial progenitor cell in diabetics with different vascular complications","volume":"89","author":"Chen","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2174\/1570159X19666210716114016","article-title":"Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment","volume":"20","author":"Zhang","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"e01035","DOI":"10.1002\/brb3.1035","article-title":"Circulating endothelial progenitor cells and endothelial cells in moyamoya disease","volume":"8","author":"Bao","year":"2018","journal-title":"Brain Behav."},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/eurheartj\/eht149","article-title":"Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I","volume":"34","author":"Paneni","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4239\/wjd.v6.i7.961","article-title":"Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes","volume":"6","author":"Thiruvoipati","year":"2015","journal-title":"World J. Diabetes"},{"key":"ref_391","first-page":"e73722","article-title":"Asymptomatic Peripheral Arterial Disease Among Jordanian Patients With Diabetic Foot Ulcer","volume":"16","author":"Younis","year":"2024","journal-title":"Cureus"},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"e000135","DOI":"10.1161\/HCQ.0000000000000135","article-title":"Understanding the Pain Experience and Treatment Considerations Along the Spectrum of Peripheral Artery Disease: A Scientific Statement From the American Heart Association","volume":"18","author":"Smolderen","year":"2025","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_393","first-page":"e82174","article-title":"Biomarkers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in Early Detection of Diabetic Foot Ulcers","volume":"17","author":"Sangeeta","year":"2025","journal-title":"Cureus"},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/14746514040040040401","article-title":"Intermittent claudication in the patient with diabetes","volume":"4","author":"Jude","year":"2004","journal-title":"Br. J. Diabetes Vasc. Dis."},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1503\/cjs.016512","article-title":"The reliability of differentiating neurogenic claudication from vascular claudication based on symptomatic presentation","volume":"56","author":"Nadeau","year":"2013","journal-title":"Can. J. Surg."},{"key":"ref_396","first-page":"e81118","article-title":"The Relationship Between Plasma Fibrinogen Levels and the Severity of Diabetic Foot Ulcers in Diabetic Patients","volume":"17","author":"Khan","year":"2025","journal-title":"Cureus"},{"key":"ref_397","first-page":"e47525","article-title":"A Comprehensive Review of the Vascular Consequences of Diabetes in the Lower Extremities: Current Approaches to Management and Evaluation of Clinical Outcomes","volume":"15","author":"Yachmaneni","year":"2023","journal-title":"Cureus"},{"key":"ref_398","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.12968\/bjon.2024.0342","article-title":"Assessment of the diabetic foot in inpatients","volume":"34","author":"Alsararatee","year":"2025","journal-title":"Br. J. Nurs."},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1161\/CIRCULATIONAHA.106.683722","article-title":"Beta2-microglobulin as a biomarker in peripheral arterial disease: Proteomic profiling and clinical studies","volume":"116","author":"Wilson","year":"2007","journal-title":"Circulation"},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/1354750X.2016.1204004","article-title":"Circulating endothelium-enriched microRNA-126 as a potential biomarker for coronary artery disease in type 2 diabetes mellitus patients","volume":"22","author":"Sabry","year":"2017","journal-title":"Biomarkers"},{"key":"ref_401","doi-asserted-by":"crossref","unstructured":"M\u00e9ndez-Vald\u00e9s, G., G\u00f3mez-Hevia, F., Lillo-Moya, J., Gonz\u00e1lez-Fern\u00e1ndez, T., Abelli, J., Cereceda-Cornejo, A., Bragato, M.C., Saso, L., and Rodrigo, R. (2023). Endostatin and Cancer Therapy: A Novel Potential Alternative to Anti-VEGF Monoclonal Antibodies. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030718"},{"key":"ref_402","doi-asserted-by":"crossref","first-page":"298239","DOI":"10.1155\/2014\/298239","article-title":"Serum endostatin concentrations are higher in men with symptoms of intermittent claudication","volume":"2014","author":"Golledge","year":"2014","journal-title":"Dis. Markers"},{"key":"ref_403","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clinbiochem.2017.12.010","article-title":"Association of vascular indices with novel circulating biomarkers as prognostic factors for cardiovascular complications in patients with type 2 diabetes mellitus","volume":"53","author":"Naka","year":"2018","journal-title":"Clin. Biochem."},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.beem.2013.08.006","article-title":"Adiponectin as a routine clinical biomarker","volume":"28","author":"Kishida","year":"2014","journal-title":"Best. Pr. Res. Clin. Endocrinol. Metab."},{"key":"ref_405","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.atherosclerosis.2017.06.019","article-title":"Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes","volume":"264","author":"Hayek","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_406","doi-asserted-by":"crossref","unstructured":"Li, B., Shaikh, F., Younes, H., Abuhalimeh, B., Zamzam, A., Abdin, R., and Qadura, M. (2025). The Prognostic Potential of Insulin-like Growth Factor-Binding Protein 1 for Cardiovascular Complications in Peripheral Artery Disease. J. Cardiovasc. Dev. Dis., 12.","DOI":"10.3390\/jcdd12070253"},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5551\/jat.48710","article-title":"Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases","volume":"26","author":"Furuhashi","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2010.07.026","article-title":"Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes","volume":"213","author":"Aragones","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_409","doi-asserted-by":"crossref","unstructured":"Li, B., Shaikh, F., Younes, H., Abuhalimeh, B., Zamzam, A., Abdin, R., and Qadura, M. (2025). Matrix Metalloproteinases 7 and 10 Are Prognostic Biomarkers for Systemic Cardiovascular Risk in Individuals with Peripheral Artery Disease. Biomolecules, 15.","DOI":"10.3390\/biom15060853"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/22\/4448\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T16:50:51Z","timestamp":1763484651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/22\/4448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":409,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["molecules30224448"],"URL":"https:\/\/doi.org\/10.3390\/molecules30224448","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}